Angel Rodríguez Nebreda has more than 30 years’ experience studying signal integration mechanisms, and during the last 15 years has focused on molecular oncology studies and the characterization of pre-clinical models of cancer. He leads a multidisciplinary team at the Cancer Science program of IRB Barcelona, currently formed by 5 Postdoctoral fellows, 5 PhD students and 2 Technicians. Altogether, these group members provide strong expertise in biochemistry and molecular and cellular biology techniques as well as in genetically modified mice and cancer preclinical models. The group has obtained founding from national and international sources, including ERC Advanced and Proof of Concept grants.
The Nebreda lab is interested in understanding basic mechanisms of cell regulation, especially in relation with how external signals are interpreted by cells to elaborate the appropriate responses. The group has made major contributions to understanding the mechanisms of signal integration by p38 MAPKs, and provided in vivo evidence for the implication of these kinases in homeostatic functions, beyond the stress response, and how dysregulation of this pathway contributes to cancer and other diseases. Recently, his lab has demonstrated important roles for p38 MAPKs in tumor progression and chemoresistance using both genetic mouse models and patient-derived xenografts. These findings have suggested new potential therapies based on p38 inhibitors, and the identification of patient groups that could benefit from them.
Main interests of the group:
– Stress-activated protein kinases
– Ringo/Speedy proteins
– Cancer cell homeostasis and chemoresistance mechanisms
– Cross talk between cancer cells and stromal cells
– Targeted therapies